Ocugen, Inc. Common Stock

OCGNNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
1.47 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
1.46
↘ 0.01 (0.68%)
POST MARKET (AS OF 07:33 PM EDT)
Post Market
AS OF 07:33 PM EDT
1.46
↘ 0.01 (0.68%)
🔴Market: CLOSED

OCGN is currently priced at $1.47. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Strong Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 10, 2026.

Open?$1.48
High?$1.49
Low?$1.41
Prev. Close?$1.47
Volume?3.5M
Avg. Volume?8.6M
VWAP?$1.45
Rel. Volume?0.41x
Bid / Ask
Bid?$1.25 × 100
Ask?$1.69 × 100
Spread?$0.44
Midpoint?$1.47
Valuation & Ratios
Market Cap?497.6M
Shares Out?338.5M
Float?322.0M
Float %?95.1%
P/E Ratio?N/A
P/B Ratio?85.72
EPS?-$0.16
Dividend?0.00%
Ex-Dividend?N/A
RelatedMRNAPFE
News
Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
116
Market Cap
497.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.ocugen.com
Listed
2014-12-03
Address
11 GREAT VALLEY PARKWAY
MALVERN, PA 19355
Phone: 484-328-4701
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
35
Short Sent.?
26
Piotroski F-Score?1/9Weak
Altman Z-Score?-7.07Distress
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?32.74%Squeeze Risk
Short Interest?105.4M
Days to Cover?7.1
Free Float322.0M
Avg Daily Volume14.9M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.86Adequate
Quick Ratio?1.86Adequate
Cash Ratio?1.54Strong
Debt/Equity?5.03High
ValuationRICHLY VALUEDvs 2 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
33
S&P
3
85.72HIGH▾
P/S?
Peers
33
S&P
3
106.83HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-10.5CHEAP▾
EV/Sales?
Peers
33
S&P
3
106.26HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
3
-929.7%WEAK▾
ROA?
Peers
50
S&P
3
-94.8%WEAK▾
Cash Flow & Enterprise
FCF?$-59576000
Enterprise Value?$495.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist